Miyashita, Hirotaka http://orcid.org/0000-0002-0433-9779
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Bevins, Nicholas J.
Thangathurai, Kartheeswaran http://orcid.org/0000-0001-7265-3922
Lee, Suzanna
Pabla, Sarabjot
Nesline, Mary
Glenn, Sean T.
Conroy, Jeffrey M.
DePietro, Paul
Rubin, Eitan
Sicklick, Jason K.
Kato, Shumei
Article History
Received: 14 January 2023
Accepted: 14 June 2023
First Online: 8 August 2023
Competing interests
: H.M. declares no competing interest. R.K. has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc., CureMetrix, and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. N.J.B. declares no competing interest. K.T. declares no competing interest. S.L. declares no competing interest. S.P., M.N., S.T.G., J.M.C. and P.DeP. hold stock in OmniSeq, Inc. E.R. declares no competing interest. J.K.S. receives research funding from Amgen Pharmaceuticals and Foundation Medicine, consultant fees from Deciphera, speaker’s fees from Deciphera, Foundation Medicine, La-Hoffman Roche, Merck, MJH Life Sciences, QED Therapeutics, and has stock in Personalis. S.K. serves as a consultant for Foundation Medicine, NeoGenomics and CureMatch. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq.